United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 7,792 shares of the business’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $358.62, for a total transaction of $2,794,367.04. Following the transaction, the chief financial officer now owns 4,802 shares in the company, valued at $1,722,093.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
James Edgemond also recently made the following trade(s):
- On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The stock was sold at an average price of $354.04, for a total transaction of $2,760,095.84.
- On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82.
- On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45.
United Therapeutics Stock Performance
Shares of United Therapeutics stock opened at $357.83 on Wednesday. The stock has a market capitalization of $15.87 billion, a price-to-earnings ratio of 16.92, a price-to-earnings-growth ratio of 1.30 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The business has a 50-day moving average of $343.01 and a 200 day moving average of $297.78. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08.
Hedge Funds Weigh In On United Therapeutics
Several institutional investors have recently modified their holdings of the business. LSV Asset Management boosted its holdings in United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares during the period. Swedbank AB purchased a new position in shares of United Therapeutics in the 1st quarter valued at about $97,316,000. Nordea Investment Management AB grew its position in shares of United Therapeutics by 677.6% during the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after buying an additional 262,222 shares in the last quarter. Avidity Partners Management LP purchased a new stake in shares of United Therapeutics during the fourth quarter worth approximately $52,158,000. Finally, Canada Pension Plan Investment Board raised its holdings in United Therapeutics by 567.2% in the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock valued at $41,533,000 after acquiring an additional 153,700 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the company. UBS Group boosted their price objective on United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. Jefferies Financial Group boosted their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. HC Wainwright restated a “buy” rating and set a $400.00 price target on shares of United Therapeutics in a report on Thursday, August 1st. Oppenheimer upped their price objective on United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a report on Wednesday, August 28th. Finally, Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $357.17.
Check Out Our Latest Research Report on United Therapeutics
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading
- Five stocks we like better than United Therapeutics
- How to Calculate Return on Investment (ROI)
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 5 Top Rated Dividend Stocks to Consider
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Investing in the High PE Growth Stocks
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.